Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Safety and Superiority Study of RP103 vs Cystagon in Cystinosis
2012-002773-64Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cysteamine in cystinosis (2 arms), sponsored by Horizon Therapeutics. Primary endpoint: Steady-state trough WBC cystine comparison RP103 vs Cystagon. Started Feb 2013; status: completed.
02
Drugs
cysteamine
03
Conditions
cystinosis
Beyond the preview
Go deeper on 2012-002773-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002773-64.